Also, the tumor immune microenvironment, particularly the presence and activity of CD8+ TILs, plays a critical role in determining immunotherapy outcomes, since cytotoxic T cells are the primary effectors of immune checkpoint inhibitors (ICIs) [23]. Here, CD8A is linked to neoplasm.